We are a spin-off of the École normale supérieure - PSL, focused on in silico drug discovery. We combine AI and disruptive structure-based affinity algorithms, which are both accurate and 10,000x faster than competition, to generate lead-like molecules for a given target.
We collaborate with innovative R&D pharmaceutical companies, biotechs & CROs and seek to build our own portfolio with dozens of internal projects. We focus on identifying or generating molecules of interest for a given project and do not sell our technology as software.
We are a team of passionate people at the crossroads of theoretical physics, medicinal chemistry and artificial intelligence.
We are seeking highly skilled, motivated and curious individuals to develop our unique science to discover new therapeutic molecules!
